A study of circulating tumor DNA in monitoring therapy and follow-up in advanced prostate cancer patients
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: null- â?¢Patients diagnosed with advanced hormone sensitive prostate cancer and planned for palliative systemic chemohormonal therapy.
- Registration Number
- CTRI/2018/01/011173
- Lead Sponsor
- Tata Memorial Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients diagnosed with advanced hormone
sensitive prostate cancer and planned for
palliative systemic chemohormonal therapy
2. Patients willing to provide written informed
consent to participate in the study
3. Patients willing to receive the usual
standard treatment, which is chemohormonal
therapy
Exclusion Criteria
•Not willing for follow up
•Not planned for systemic therapy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To identify the mutations in the 32 genes from Qiagen Prostate Cancer Gene Read DNA seq Targeted Panel and subtract these mutations from the background germline DNA (from buffy coat DNA).Timepoint: Two years
- Secondary Outcome Measures
Name Time Method 2.To characterize these identified mutations. <br/ ><br>3.To use these mutations in blood to monitor response to therapy. <br/ ><br>4.To evaluate whether tumour burden relates quantitatively to ctDNA. <br/ ><br>5.To use these markers (in a personalized patient specific manner) to monitor therapy and progression by quantifying the same mutations in peripheral blood. <br/ ><br>Timepoint: Two years